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Liability Issues in Pharmacogenomics
MarkA. Rothstein
Liability concerns involving pharmacogenomics inevitably
raise broad issues of ethics and policy. The first of these issues,
often called "genetic exceptionalism," deals with whether genetic
information is so unique that it should be considered separately
from other medical information.
In other words, is there
something different about pharmacogenomics as opposed to any
other pharmaceutical research discipline? Is there something
unique about drug development strategies and drug regulation
involving pharmacogenomics compared with traditional drug
development strategies and regulations?
Is there something
different about liability issues for manufacturers and health care
providers involved with this technology? These questions will
inform our analysis of pharamacogenomics.
Another important, overarching issue is the effect on liability
of increasingly sophisticated medical technologies. In medicine,
the more that health care providers attempt or promise they can do,
the greater the likelihood that patients and their family members
will be disappointed after an adverse outcome. Disappointment,
personal loss, and high health care expenses sometimes translate
into lawsuits. But, I am getting ahead of myself, and first I want to
trace the ethical, policy, and potential liability issues all the way
back to the research stage.
Let us assume that I am the CEO of a large biotech or
pharmaceutical company engaged in research on a certain disease.
Scientists working for my company discover that there are ten
common polymorphisms of a particularly promising drug target.
We can design drugs to attack one, two, or maybe three of these
polymorphisms, but it would be prohibitively expensive to design a
drug strategy and do research on all ten gene variations. How do I
decide which polymorphism to pursue? If I am a savvy CEO, the
first thing I am going to ask is, "Tell me what the market is for
each of these ten potential drug targets." I want to know more than
simply the overall population frequency; I want to know who these
people are. Are they likely to be well-insured, or otherwise have
money? Where do they live? If they live in developing countries,
I doubt I would be interested in spending one hundred million
Copyright 2005, by LOUISIANA LAW REVIEW.
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dollars on research and development ("R&D") to make a product
that few potential customers could afford to buy.
From the standpoint of distributional ethics, how do we decide
what drug targets are appropriate? The answer involves more than
simply rich and poor. It may be a matter of numbers. As a drug
company CEO, I'm also not interested in spending money to find
drugs for rare genotypes-what may be called "orphan genotypes."
Should public policy be formulated to try to promote the research
and development of drugs aimed at rare genetic variations? One
possibility is to enact legislation along the lines of the Orphan
Drug Act to help subsidize such drug development.
As for liability, the two main legal theories likely to be raised
by individuals who allege that they were injured by taking a
pharmacogenomic-based medication are products liability and
negligence. Products liability would be used in actions against
manufacturers and retailers of pharmaceutical products. For those
of you not familiar with the concept of products liability, it is
liability without fault. That means there is no requirement that the
injured party prove the manufacturer failed to exercise reasonable
care in designing or manufacturing the drug.3 The main theory
behind strict liability for dangerously defective products is that the
costs of injuries are allocated to the manufacturers of the products,
who are more able to bear the costs and pass them on to the
ultimate consumers of the products. In this way, the costs of
injuries are distributed amon all users rather than the unfortunate
ones with adverse outcomes. Negligence is the most likely legal
theory on which to base a lawsuit against a health care professional
who erroneously prescribed a particular pharmaceutical product.
In such a case, the allegations would be similar to those in medical
malpractice cases---that the health care provider failed to meet a
reasonable standard of care. 5
Another legal theory that could be used in lawsuits against
pharmaceutical companies is failure to warn. 6 Manufacturers have
a legal duty to warn consumers of dangers flowing from both the
intended uses of their product and the foreseeable misuses of their
product. Did you ever wonder why ladder manufacturers put a
1. 21 U.S.C. §§ 360aa-360ee (2004).
2. Larry I. Palmer, Medical Liability for Pharmacogenomics,
Pharmacogenomics: Social, Ethical, and Clinical Dimensions (Mark A.
Rothstein ed., 2003).
3. David G. Owen, Products Liability Law 249 (2005).
4. 2 Dan B. Dobbs, The Law of Torts, 976-77 (2000).
5. 1Dan B. Dobbs, The Law of Torts, 632-33 (2000).
6. Owen, supranote 3, at 564.
7. Id. at 853.
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warning on the little ledge that holds the paint can that says, "This
is not a step?" The answer is that, even though it is a foolish thing
to do, it is foreseeable that someone will try to use the ledge as a
step, fall off, and suffer serious injuries. The law has developed to
hold that if a product's misuse is foreseeable, then the
manufacturer may be liable if it failed to take steps to protect the
consumer, including warnings about the dangers of misusing the
product. In the pharmaceutical setting, manufacturers satisfy the
duty to warn through warning labels, package inserts, and product
descriptions in the Physician's Desk Reference.
Although research in pharmacogenomics has a long way to go,
there is already litigation in this area. Pharmacogenomic-based
products are not a prerequisite for pharmacogenomic-inspired
litigation. As soon as it is possible to detect varied response to a
pharmaceutical product, manufacturers may have a duty to inform
potential users of that variation and suggest that they undergo
genetic testing, even though there is no special product, special
dosage, or other attempt to target the product to a particular
genotype.8 Here, the duty to warn involves warnings about
potential adverse events identifiable by genetic testing.
An important concept in failure to warn cases is the "learned
intermediary doctrine." 9 This doctrine is premised on the fact that,
with a prescription drug, there are at least two levels of
professionals between the patient and the product--the prescribing
physician and the distributing pharmacist.
Pharmaceutical
companies have a reasonable expectation that the patient will be
told by a prescribing physician how to take the prescription and
that there will be directions given to the patient by the
pharmacist-how many pills to take, what time of day, with or
without food, etc. The defendant-manufacturer may rely on these
other professionals to provide instructions as long as the learned
intermediaries themselves have been given sufficient information
about what to tell the patient.
Another important issue in pharmaceutical litigation involves
off-label uses. The Food and Drug Administration (FDA) does not
regulate the practice of medicine; it regulates drugs and devices.
The FDA is not in the business of telling physicians for what
conditions they can prescribe medications. The main exceptions
involve information the FDA compels manufacturers to put on the
8. Mark A. Rothstein, Epilogue: Policy Prescriptions, Pharmacogenomics:
Social, Ethical, and Clinical Dimensions 327 (Mark A. Rothstein ed., 2003).
9. James 0. Castagnera et al., The GradualEnfeeblement of the Learned
Intermediary Rule and the Argument in Favor of Abandoning It Entirely, 36

Tort & Ins. L.J. 119 (2000-2001).

LOUISIANA LAW REVIEW

[Vol. 66

label or package insert, and "Dear Doctor" letters advising
physicians of newly discovered problems involving certain
medications. Therefore, if a physician thinks that a medication for
asthma will work wonders for patients with diabetes, the FDA is
not going to limit the ability of the physician to prescribe this socalled off-label use. Nevertheless, if a manufacturer promotes a°
harmful off-label use, then the manufacturer may be found liable.'
There have been instances where a manufacturer has "winked" at
an off-label use because the use greatly increased the market for
the product. In the future, it is at least theoretically possible that a
pharmaceutical company, that has invested millions of dollars for a
genetically-limited drug, would have an incentive to encourage
wider off-label use.
Direct-to-consumer (DTC) advertising 1 poses yet another
liability issue. It is difficult to imagine that it is only in the last ten
years that there has been such a seemingly endless barrage of
commercials during the evening news for new pharmaceutical
products. Manufacturers have realized that DTC advertising is a
very effective way to stimulate demand for their products. Now, I
have to admit that some of these commercials absolutely baffle me.
They must work or the drug companies would not spend such great
sums of money making and airing them, but sometimes I don't see
the point of advertising directly to consumers. One product that
comes to mind is Procrit. The voiceover says something like:
"Are you undergoing chemotherapy? Are you weak? Do you
have anemia? Do you have a hard time walking? Ask your doctor
about Procrit." I can't help but think, if I am on chemotherapy and
having those problems, my doctor had better not wait for me to tell
him or her about medications to alleviate such debilitating
symptoms.
At any rate, absent a .regulatory change, DTC
advertising is not going away, and it is likely to be increasingly
important for a wide range of pharmaceutical products.
The intersection of DTC advertising and pharmacogenomics
raises some important ethical issues involving race and ethnicity.
Scientists may well discover certain individuals in certain
culturally defined groups who have a much higher incidence of X,
Y, or Z condition. They may also discover that some treatments
work better for people with certain genotypes linked in one way or
another to a certain ethnic group. And I can imagine the
10. Margaret Gilhooley, When DrugsAre Saferfor Some But Not Others:
The FDA Experience andAlternatives for Products Liability, 36 Hou. L. Rev.
927, 939 (1999).
11. Food and Drug Administration, Final Guidance on Direct-to-Consumer
Advertising, 64 Fed. Reg. 43, 197 (1999).
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announcers on the commercials asking: "Are you AfricanAmerican? Do you have hypertension? My company has just
developed a new drug for you." Or: "Are you of Hispanic origin?
Do you have diabetes? We've got a drug for you." And I think
this would be just awful in terms of fostering the public's
misunderstanding of the relationship between genotype, "race and
ethnicity," and adverse drug reactions in certain groups.
Unfortunately, I can see it happening unless we are careful.
I also think that post-marketing surveillance may be
increasingly important as there are more clinical trials involving
genotype-matched subjects.
Compliance by pharmaceutical
manufacturers with their post-marketing surveillance obligations
has been lagging. 12 Many experts believe that clinical trials in
smaller and genetically homogeneous cohorts may miss potentially
adverse drug events. Therefore, post-marketing surveillance will
be increasingly important.
One last type of pharmacogenomics inspired lawsuit might
arise out of the use of home testing kits to detect
pharmacogenomic variations.
It does not take too much
imagination to contemplate the sale of such a product, perhaps
with instructions to match your dosage to blue, red, purple, or
whatever color your sample turns. I think we need to be very
careful before we turn every residential bathroom into a clinical
pharmacogenomics laboratory. I think it is reasonable to predict
that adverse events from such do-it-yourself pharmacy practice
will inevitably result in litigation.
The preceding discussion has focused on special litigation
issues raised by pharmacogenomics. In addition, "traditional"
personal injury lawsuits may implicate pharmacogenomics. For
example, managed care organizations (MCOs) often adopt
formularies of medications for which they will provide payment
under a particular health plan. The decisions whether to include a
pharmaceutical product on a formulary are extremely important to
the diffusion of any new product. Without reimbursement, the
uptake of the technology will be low because people do not like to
pay out-of-pocket. MCOs will have to undertake a drug-by-drug
cost-benefit analysis to determine whether a pharmacogenomic test
to identify differential drug response and prescribing the new drug
indicated by the test are cost-effective. For example, a drug may
be ten percent more efficacious, but cost twenty times more than
standard therapy. The decision whether to cover the new drug will
be based on the degree of efficacy of standard therapy, the nature
12. Food and Drug Administration, Report to Congress on Postmarketing
Studies (2003), availableat www.fda.gov/cber/fdama/pstmrktfdama 130.htm.
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of the condition, the degree to which timing is essential to
treatment, and numerous other factors. Suppose that the formulary
does not include a certain drug because the MCO has determined
that the benefits are not significant when compared with the cost.
Does the physician have an obligation to tell the patient the
following: "There is another drug that studies show may be a little
bit more effective, but it is much more expensive, and your health
plan does not pay for it. So, if you want that drug, I will write you
a prescription, but keep in mind that it will cost you around $400 a
month for this drug, and the other would be completely paid for by
your insurance." Would there be liability for the physician who
fails to provide this information when the patient does not get
better using the formulary medication?
If current trends continue, one of the most likely ways we are
going to see pharmacogenomic testing introduced commercially is
to rule out certain drugs that would cause side-effects to the
patient. I suspect that before we actually have replacement drugs,
some of these tests will be used as a safety screen. If physicians
fail to use them and an adverse event occurs, there could be
liability. A fundamental question is whether physicians have the
training to incorporate these tests and products into their practices.
In the past, medical genetics was largely the domain of
obstetricians, pediatricians, and a handful of specialties besides the
genetics field itself. In the future, pharmacogenomics will be
integrated into all medical specialties and in the practices of
generalists as well. For example, in the future internists may be
unlikely to prescribe medications for diabetes or hypertension
unless the patient first undergoes some pharmacogenomic analysis.
Clinical pharmacogenomics may also increase the responsibilities
of clinical laboratories. Who is going to teach and attend all of
those Continuing Medical Education programs? And how much
information will a laboratory have to report to an ordering
physician about the outcome of the test?
Another potential source of malpractice liability for physicians,
nurses, and pharmacists is the failure to provide genetic
counseling. Keep in mind that counseling for pharmacogenomics
would not be the typical genetic counseling-for example, before
someone decides to take a cystic fibrosis carier test. But, even
beyond medicinal and psychological implications, the outcomes of
these tests could bring about negative economic consequences to
the patient by adding information to the individual's health record
that he or she is more difficult or expensive to treat.
13. Ellen Wright Clayton, Ethical,Legal andSocial Implicationsof Genetic
Medicine, 349 New Eng. J. Med. 562 (2003).
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The economics of genetic testing are also likely to raise more
challenges for genetic counseling. For the cost of testing for a
single pharmacogenomic variation, why not test for 1,000 or
10,000 polymorphisms and build the record for future medicinal
needs? How can a health care provider get informed consent for so
many tests being run at the same time? Today, a single informed
consent is used for multi-test panels; should a different approach
When
be used with genetic or pharmacogenomic tests?
considering genetic counseling in the primary care setting, an
important question that comes to mind is: Who is going to do this?
Who has time for it? Who is going to reimburse for the
counseling? Because the answer to all of these questions is usually
"nobody," it is essential to identify other mechanisms to assist with
the counseling function, including web-based education,
interactive CDs, and so forth. Keep in mind that people tend not to
understand probability and risk, and they do not understand
concepts like expressivity, penetrance, and latency. Consequently,
genetic counseling is highly complex.
Another potential source of malpractice liability is the failure
to provide warnings to at-risk relatives. A few years ago, the
American Society of Human Genetics issued a statement that it
would be permissible for physicians and non-physician geneticists
to warn at-risk relatives when a patient's refusal to warn could
result in imminent harm. 14 It is not clear whether this advice
remains valuable in light of the Privacy Rule promulgated under
the Health Insurance Portability and Accountability Act
(HIPAA). 5
It also remains to be seen whether personal injury lawsuits
based on alleged failure to properly prescribe, dose, dispense, and
administer medications will increase as a result of the growing
availability of pharmacogenomic based drugs. If so, there could
well be a significant increase in the potential liability of
pharmacists and nurses as well as physicians. Of course, no
plaintiff is going to sue a nurse rather than a physician unless the
nurse's wrongdoing means liability for a hospital. After all,
pharmacogenomics is unlikely to change the need for a malpractice
plaintiff to find a deep pocket.
As in other aspects of health care, concerns about liability may
prove to be a key factor that drives the adoption of
pharmacogenomic tests and medications. Consider the following

14. ASHG Social Issues Subcommittee on Familial Disclosure, Professional
Disclosure of Familial Genetic Information, 62 Am. J. Hum. Genet. 474 (1998).
15. 45 C.F.R. pts. 160, 164 (2005).
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example: the adoption of non-ionic contrasts in IVPs' 6 and other
imaging procedures. It is well known that a small percentage of
the population is allergic to iodine-based ("ionic") solutions and a
small number of individuals have even gone into anaphylactic
shock and died. Moreover, when first introduced to the market in
the 1980s, non-ionic contrasts cost about one hundred dollars for a7
sixty cc. bottle, whereas ionic contrasts cost about six dollars.'
Why, then, would there be an immediate move to adopt the more
expensive contrasts? Imagine a courtroom and a radiologist is
being sued for the wrongful death of a patient who died after a
severe reaction to an ionic contrast. The plaintiffs lawyer's
questioning of the defendant might go something like this: "Now,
Dr. Jones, isn't it a fact that Mr. Smith would be alive today if you
spent an additional ninety-four dollars to give him the safest
available contrast solution? Do you think Mr. Smith's life was
worth ninety-four dollars?"
The point is clear. Obviously,
physicians don't want their patients to suffer adverse reactions, but
they also don't want to be in the position of defending their failure
to provide the best care because of a relatively small difference in
cost for each patient, notwithstanding the aggregate effect on
health care expenditures. I think it is easy to extend this thinking
to new, presumably more expensive, pharmacogenomic therapies.
I want to close by emphasizing the importance of not losing
sight of the big picture. First, we would be remiss if we allowed
liability concerns to paralyze either drug development or the
clinical introduction of safer and more effective pharmacogenomic
medications. Although the liability issues I have mentioned are
potential impediments, they are not insurmountable. Second, we
must remember the overall state of access to prescription
medications. We are in the process of creating potentially more
exotic and more expensive medications at a time when millions of
people in the United States and billions of people worldwide lack
access to the cheap, off-patent medications that have been around
for years. We must continue to work to ensure that people
everywhere have access to medications that make a significant,
proven difference in human health while simultaneously
researching pharmacogenomics.

16. An intravenous pyelogram is an x-ray examination of the kidneys,
ureters, and urinary bladder.
Radiological Society of North America,
Intravenous Pyelogram (IVP) Radiography (X-Ray), www.radiologyinfo.org/
content/ivpradiology.htm.
17. Frank E. James, Doctors Debate Use in Tests ofSafer but CostlierDyes,
Wall St. J., Dec. 2, 1988.

